Ryuto Otsuka1, Narumi Kubo1, Yosuke Miyazaki1, Mio Kawahara1, Jun Takaesu1, Kazuki Fukuchi2. 1. Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka, 565-0871, Japan. 2. Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka, 565-0871, Japan. kfukuchi@ga2.so-net.ne.jp.
Abstract
BACKGROUND: Ionizing radiation generated during medical imaging procedures is a matter of concern. However, the current status of radiopharmaceutical use in stress myocardial perfusion imaging (MPI) and the radiation exposure from these radiopharmaceuticals is unknown in Japan. METHODS AND RESULTS: A nationwide survey was conducted from June through July 2016. The questionnaires on the radiopharmaceuticals used and their administered doses during stress MPI were sent to 641 nuclear medicine facilities. The responses were collected from 431 facilities and the effective dose (ED) for an adult with standard body weight was calculated. Forty-three percent of the facilities used only 201TlCl, 35% used only 99mTc radiopharmaceuticals, and the remaining 22% used both. The two main reasons for using 201TlCl instead of 99mTc radiopharmaceuticals were "more familiarity with the usage of 201TlCl than 99mTc radiopharmaceuticals" and "apprehension about increasing the burden of physicians performing tracer injection twice." The mean ED was 14.0 ± 5.5 mSv (range, 3.9 to 25.2 mSv), which was higher than that reported in other countries. CONCLUSIONS: The ED of stress MPI radiopharmaceuticals in Japan is probably higher than the world standard because more than 50% of the facilities still use 201TlCl. We recommend revising the routine stress MPI protocol to reduce the effects of ionizing radiation.
BACKGROUND:Ionizing radiation generated during medical imaging procedures is a matter of concern. However, the current status of radiopharmaceutical use in stress myocardial perfusion imaging (MPI) and the radiation exposure from these radiopharmaceuticals is unknown in Japan. METHODS AND RESULTS: A nationwide survey was conducted from June through July 2016. The questionnaires on the radiopharmaceuticals used and their administered doses during stress MPI were sent to 641 nuclear medicine facilities. The responses were collected from 431 facilities and the effective dose (ED) for an adult with standard body weight was calculated. Forty-three percent of the facilities used only 201TlCl, 35% used only 99mTc radiopharmaceuticals, and the remaining 22% used both. The two main reasons for using 201TlCl instead of 99mTc radiopharmaceuticals were "more familiarity with the usage of 201TlCl than 99mTc radiopharmaceuticals" and "apprehension about increasing the burden of physicians performing tracer injection twice." The mean ED was 14.0 ± 5.5 mSv (range, 3.9 to 25.2 mSv), which was higher than that reported in other countries. CONCLUSIONS: The ED of stress MPI radiopharmaceuticals in Japan is probably higher than the world standard because more than 50% of the facilities still use 201TlCl. We recommend revising the routine stress MPI protocol to reduce the effects of ionizing radiation.
Authors: Andrew J Einstein; Thomas N B Pascual; Mathew Mercuri; Ganesan Karthikeyan; João V Vitola; John J Mahmarian; Nathan Better; Salah E Bouyoucef; Henry Hee-Seung Bom; Vikram Lele; V Peter C Magboo; Erick Alexánderson; Adel H Allam; Mouaz H Al-Mallah; Albert Flotats; Scott Jerome; Philipp A Kaufmann; Osnat Luxenburg; Leslee J Shaw; S Richard Underwood; Madan M Rehani; Ravi Kashyap; Diana Paez; Maurizio Dondi Journal: Eur Heart J Date: 2015-04-21 Impact factor: 29.983
Authors: Oliver Lindner; Thomas N B Pascual; Mathew Mercuri; Wanda Acampa; Wolfgang Burchert; Albert Flotats; Philipp A Kaufmann; Anastasia Kitsiou; Juhani Knuuti; S Richard Underwood; João V Vitola; John J Mahmarian; Ganesan Karthikeyan; Nathan Better; Madan M Rehani; Ravi Kashyap; Maurizio Dondi; Diana Paez; Andrew J Einstein Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-19 Impact factor: 9.236
Authors: Firas J Al Badarin; John A Spertus; Timothy M Bateman; Krishna K Patel; Eric V Burgett; Kevin F Kennedy; Randall C Thompson Journal: J Nucl Cardiol Date: 2019-01-31 Impact factor: 5.952